Copanlisib

Mar 31, 2020

MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma

Jul 01, 2019

Global Aliqopa (Copanlisib; Bayer) Drug Profile 2019: A Small Molecule Phosphoinositide 3-Kinase (PI3K) Inhibitor with High Selectivity for the p110-alpha/delta Catalytic Subunits

May 29, 2019

Bayer Receives U.S. FDA Breakthrough Therapy Designation for Aliqopa(TM) (copanlisib) for the Treatment of Marginal Zone Lymphoma

Mar 27, 2019

Bayer Data at AACR 2019 Underscores Company's Commitment to Advancing the Future of Cancer Care

May 03, 2018

Forty Seven, Inc. Granted Fast Track Designation for 5F9 for the Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Dec 07, 2017

Bayer to Highlight New Research at ASH 2017

Dec 07, 2017

Bayer to Highlight New Research at ASH 2017

Sep 14, 2017

FDA approves new treatment for adults with relapsed follicular lymphoma

Sep 14, 2017

Bayer Receives FDA Approval for Aliqopa(TM) (copanlisib) 60 mg vial for Injection in Adults with Relapsed Follicular Lymphoma after Two Prior Systemic Therapies